Autologous stem cell therapy - CellPraxis/Cryopraxis

Drug Profile

Autologous stem cell therapy - CellPraxis/Cryopraxis

Alternative Names: MonoCell; ReACT; Refractory angina cell therapy

Latest Information Update: 13 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CellPraxis; Cryopraxis
  • Class Antineoplastics; Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Angina pectoris

Most Recent Events

  • 13 Aug 2015 No recent reports on development identified - Phase-II for Angina pectoris (Treatment-experienced) in Brazil (Intracardiac)
  • 06 Nov 2012 Cryopraxis and CellPraxis plan a Phase-III trial for Angina pectoris (treatment-experienced patients) in Brazil
  • 31 Dec 2011 Cryopraxis and CellPraxis complete a Phase-II trial in Angina pectoris (treatment-experienced patients) in Brazil
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top